Denosumab for the treatment of osteoporosis: A systematic literature review

Reumatologia Clinica

Volumn 9, Issue 1, 2013, Pages 42-52

  Silva Fernández, Lucía ^a   Rosario, María Piedad ^b   Martínez López, Juan Antonio ^c   Carmona, Loreto ^d,e   Loza, Estibaliz ^e  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b UNIDAD DE INVESTIGACIÓN   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^e Instituto de Investigación Musculo esquelética inMusc   (Spain)

Author keywords

Denosumab; Efficacy; Osteoporosis; Safety; Systematic literature review

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; PLACEBO;

ARTICLE; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; HUMAN; LUMBAR SPINE; META ANALYSIS; NEOPLASM; OSTEOPOROSIS; PAIN; PROPHYLAXIS; SIDE EFFECT; SINGLE DRUG DOSE; SPINE FRACTURE; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MODELS, STATISTICAL; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84872781687     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.06.007     Document Type: Article

References (53)

1. Burkiewicz J.S., Scarpace S.L., Bruce S.P. Denosumab in osteoporosis and oncology. Ann Pharmacother 2009, 43:1445-1455.
2. NIH Consensus Development Panel on osteoporosis prevention, diagnosis, therapy, March 7-29, 2000: highlights of the conference. South Med J 2001, 94:569-573.
3. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
4. Kostenuik P.J., Bolon B., Morony S., Daris M., Geng Z., Carter C., et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004, 34:656-664.
5. Capparelli C., Morony S., Warmington K., Adamu S., Lacey D., Dunstan C.R., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003, 18:852-858.
6. Charopoulos I., Orme S., Giannoudis P.V. The role and efficacy of denosumab in the treatment of osteoporosis: an update. Expert Opin Drug Saf 2011, 10:205-217.
7. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
8. Beck T.J., Lewiecki E.M., Miller P.D., Felsenberg D., Liu Y., Ding B., et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 2008, 11:351-359.
9. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
10. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
11. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
12. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
13. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
14. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
15. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
16. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
17. Seeman E., Delmas P.D., Hanley D.A., Sellmeyer D., Cheung A.M., Shane E., et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
18. Monoclonal antibody demonstrates efficacy in postmenopausal osteoporosis. Formulary 2006, 41.
19. Drugs for postmenopausal osteoporosis. Treat Guidel Med Lett 2008, 6:67-74. [quiz 5-6].
20. Molecule of the Month. Denosumab. Drug News Perspect 2009, 22:356.
21. Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Obstet Gynecol Surv 2009, 64:805-807.
22. Ecker-Sclipf B. Denosumab: new treatment possibility for the prevention of bone loss. Arzneimitteltherapie 2010, 28:102-103.
23. Favus M.J. Does denosumab improve low BMD in postmenopausal women?. Nat Clin Pract Endocrinol Metab 2006, 2:600-601.
24. Lewiecki E.M. Denosumab for the treatment of postmenopausal osteoporosis. Womens Health (Lond Engl) 2009, 5:15-22.
25. Eastell R., Christiansen C., Grauer A., Kutilek S., Libanati C., McClung M.R., et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:530-537.
26. Genant H.K., Engelke K., Hanley D.A., Brown J.P., Omizo M., Bone H.G., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
27. Kendler D.L., McClung M.R., Freemantle N., Lillestol M., Moffett A.H., Borenstein J., et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011, 22:1725-1735.
28. Reid I.R., Miller P.D., Brown J.P., Kendler D.L., Fahrleitner-Pammer A., Valter I., et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25:2256-2265.
29. Miller P.D., Wagman R.B., Peacock M., Lewiecki E.M., Bolognese M.A., Weinstein R.L., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011, 96:394-402.
30. Boonen S., Adachi J.D., Man Z., Cummings S.R., Lippuner K., Torring O., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011, 96:1727-1736.
31. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Miller P.D., Yang Y.C., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011, 96:972-980.
32. Silverman S., Viswanathan H., Wang A., Ragi-Eis S., Fardellone P., Gilchrist N., et al. Evaluation of health-related quality of life in postmenopausal women with osteoporosis who participated in the FREEDOM trial [abstract]. Osteoporos Int 2010, 21:S14.
33. Rizzoli R., Boonen S., Bone H.G., Minisola S., Wang A., Benhamou C.L., et al. The effect of denosumab on vertebral fracture risk by type and subgroup: results from the FREEDOM trial [abstract]. Osteoporos Int 2010, 21:S357.
34. Boonen S., McClung M.R., Minisola S., Lippuner K., Törring O., Rizzoli R., et al. Antifracture effects of denosumab in postmenopausal women at higher fracture risk: a subgroup analysis from the FREEDOM trial [abstract]. Osteoporos Int 2010, 21:S376.
35. Adami S., Libanati C., Adachi J., Boonen S., Cummings S., de Gregorio L.H., et al. Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: results from the FREEDOM trial [abstract]. J Bone Miner Res 2010, 25. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=d136b49f-5ddd-453a-a5a6-c1a5de7e5d4e%5D [accessed April, 2011].
36. Keaveny T., McClung M.R., Genant H.K., Zanchetta J.R., Kendler D.L., Brown J., et al. Denosumab improves both femoral and vertebral strength in women with osteoporosis: results From the FREEDOM trial [abstract]. J Bone Miner Res 2010, 25. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=4f3ef6f9-bc5b-40e7-870a-acdd7fa90ede%5D [accessed April, 2011].
37. Papapoulos S.E., Bone H.G., Brandi M.L., Brown J., Chapurlat R., Czerwinski E., et al. Four years of denosumab exposure in women with postmenopausal osteoporosis: results from the first year extension of the FREEDOM trial [abstract]. J Bone Miner Res 2010, 25. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=bf987496-1278-41ba-9bc5-a24df0956414%5D [accessed April, 2011].
38. Genant H.K., Zanchetta J., Hoiseth A., Yuen C.K., Stonkus S., Bolognese M.A., et al. Hip QCT results from the FREEDOM trial: evidence for positive BMD/BMC changes in integral, trabecular, and cortical bone with denosumab [abstract]. J Bone Miner Res 2010, 25. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=501628ff-8eee-4f64-be5b-ab2ab9107921%5D [accessed April, 2011].
39. Wagman R.B., Brown J., Dempster D.W., Ding B., Dent R., San Martin J., et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment [abstract]. Arthritis Rheum 2010, 62:2161.
40. Bouxsein M.L., Delmas P.D. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 2008, 23:1155-1167.
41. Ross P.D., Genant H.K., Davis J.W., Miller P.D., Wasnich R.D. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 1993, 3:120-126.
42. Wasnich R.D., Ross P.D., Davis J.W., Vogel J.M. A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J Nucl Med 1989, 30:1166-1171.
43. Cummings S., Lui L.Y., Vittinghoff E., Eastell R., Austin M., Boonen S., et al. The value of monitoring hip BMD during treatment with denosumab: one year changes in BMD and reductions in fracture risk [abstract]. J Bone Miner Res 2010, 25. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=aa6fec30-6733-47bc-aa94-2a9a7e5ff2d9%5D [accessed April, 2011].
44. Cummings S., Yang Y.C., Vittinghoff E., Adami S., Bianchi G., Bolognese M.A., et al. Increases in BMD on denosumab explains much of the reduction in fracture risk [abstract]. J Bone Miner Res 2009, 24. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=c35771c0-a4d0-4fa0-bd6b-75bbfea865b6%5D [accessed April, 2011].
45. Cranney A., Tugwell P., Cummings S., Sambrook P., Adachi J., Silman A.J., et al. Osteoporosis clinical trials endpoints: candidate variables and clinimetric properties. J Rheumatol 1997, 24:1222-1229.
46. Adachi J.D. The correlation of bone mineral density and biochemical markers to fracture risk. Calcif Tissue Int 1996, 59(Suppl. 1):16-19.
47. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992, 7:1251-1258.
48. Bachmann M.F., Wong B.R., Josien R., Steinman R.M., Oxenius A., Choi Y. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999, 189:1025-1031.
49. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
50. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
51. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
52. Kothawala P., Badamgarav E., Ryu S., Miller R.M., Halbert R.J. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007, 82:1493-1501.
53. Siris E.S., Harris S.T., Rosen C.J., Barr C.E., Arvesen J.N., Abbott T.A., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022.